Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 5:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–88 of 88 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Premier Research Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Multi-center, Open-label, Randomized, Parallel Group Study to Evaluate Pharmacokinetic Profile, Effects on the Mechanisms of Contraceptive Efficacy and Safety of Two Progestin-only Patches Containing Different Doses of Levonorgestrel (LNG)

NCT01166412
View directory record Official record
Conditions
Contraception
Interventions
levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2, levonorgestrel patch with BMI <32 kg/m2
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
6
States / cities
Aurora, Colorado • New York, New York • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 9, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

NCT04608500
View directory record Official record
Conditions
Facial Papulopustular Rosacea
Interventions
FMX103 minocycline foam 1.5%, Vehicle foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
771 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
46
States / cities
Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 9, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder

NCT04044664
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Placebo oral capsule, NYX-783
Drug
Lead sponsor
Aptinyx
Industry
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
37
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 9, 2026, 5:49 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of A Collagen Bupivacaine Implant in Patients After Gastrointestinal Surgery

NCT00661466
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Bupivacaine Collagen Sponge, Placebo
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Oct 9, 2026, 5:49 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia

NCT05778188
View directory record Official record
Conditions
Hypoxic-Ischemic Encephalopathy
Interventions
RLS-0071, Placebo
Drug
Lead sponsor
ReAlta Life Sciences, Inc.
Industry
Eligibility
Up to 10 Hours
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 9, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics, Relative Bioavailability and Safety of Xaracoll Implant

NCT02232178
View directory record Official record
Conditions
Hernioplasty
Interventions
2 100mg Xaracoll implants, 3 100mg Xaracoll implants, 150mg Bupivacaine HCl injection
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Anniston, Alabama • Sheffield, Alabama • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 9, 2026, 5:49 AM EDT
Terminated Phase 3 Interventional Results available

A Trial to Determine the Efficacy and Safety of Presendin in IIH

NCT05347147
View directory record Official record
Conditions
Idiopathic Intracranial Hypertension
Interventions
Presendin, Placebo
Drug
Lead sponsor
Invex Therapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Aurora, Colorado • Miami, Florida • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 9, 2026, 5:49 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens

NCT05216510
View directory record Official record
Conditions
Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2
Interventions
TNX-2110, TNX-2120, TNX-2130, CANDIN, Diluent
Biological
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 9, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of the CollaRx Bupivacaine Implant Compared to the ON-Q Painbuster Following Abdominal Hysterectomy

NCT00749749
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant), ON-Q PainBuster Post-op Pain relief System
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Boynton Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 9, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy Study of Two Continuous Regimens of Oral Daily 5 mg or 10 mg of Ulipristal Acetate (UPA), Versus a Dose of 5.0mg UPA for 24/4 Days

NCT01953679
View directory record Official record
Conditions
Focus: Estrogen-free Oral Contraception
Interventions
Ulipristal Acetate
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 9, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection

NCT00600483
View directory record Official record
Conditions
Cardiac Surgery, Sternal Wound Infection
Interventions
gentamicin-collagen sponge dipped in saline
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years and older
Enrollment
1,502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
43
States / cities
Birmingham, Alabama • Florence, Alabama • Pasadena, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 9, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

NCT04994483
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Simufilam, Placebo
Drug
Lead sponsor
Cassava Sciences, Inc.
Industry
Eligibility
50 Years to 87 Years
Enrollment
804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
74
States / cities
Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 9, 2026, 5:49 AM EDT
Completed Phase 2 Interventional

Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion

NCT00073554
View directory record Official record
Conditions
Arterial Occlusive Diseases, Peripheral Vascular Diseases, Thrombosis
Interventions
Alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 17, 2009 · Synced Oct 9, 2026, 5:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose, Dose-Ranging Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men

NCT02754687
View directory record Official record
Conditions
Healthy Men, Male Contraception
Interventions
Placebo, 11βmethyl nortestosterone dodecylcarbonate
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Torrance, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 9, 2026, 5:49 AM EDT
Not listed Phase 3 Interventional

Safety, Tolerability, PK, and Analgesic Effect of INL-001 in Children Following Open Inguinal Hernia Repair

NCT03262688
View directory record Official record
Conditions
Inguinal Hernia, Postoperative Pain
Interventions
Bupivacaine HCl collagen-matrix implant, Bupivacaine HCl infiltration
Drug
Lead sponsor
Innocoll
Industry
Eligibility
2 Years to 16 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
11
States / cities
Laguna Hills, California • Altamonte Springs, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 9, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Pharmacokinetic Profile of a Collagen Bupivacaine Implant in Men After Open Mesh Herniorrhaphy

NCT00626886
View directory record Official record
Conditions
Postoperative Pain, Inguinal Hernia
Interventions
Bupivacaine Collagen Sponge, placebo collagen sponge
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 9, 2026, 5:49 AM EDT